TX-FLUENCE
19.10.2021 15:02:06 CEST | Business Wire | Press release
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today it will debut products at MJBizCon 2021, including its high-output SPYDR 2h, SPYDR Fang, waterproof RAZR Enclosed and next-generation RAPTR top light as well as its new lighting controls, Wireless Flex Dimming and the SHYFT Light Scheduler.
Following the announcement of its multiyear global research study results —which showcased the effects of broad-spectrum lighting solutions on crop yield and quality—Fluence will demo its innovative new products at the company’s MJBizCon booth, located at No. C3515.
“In our recently announced research results, Fluence noted a clear, positive impact on cannabis crop yield, cannabinoid content and overall plant quality under broad-spectrum lighting,” said David Cohen, CEO of Fluence. “According to the 2021 State of the Cannabis Lighting Market report , LED usage for cannabis cultivation has increased more than 45 percent for all stages of growth since the initial report in 2016. The efficacy of LED lighting solutions for cannabis cultivation is no longer a question. Cultivators have embraced the power of LEDs and are seeking new ways to harness broad-spectrum lighting technology to optimize their cultivation environments. Fluence’s innovative new products—informed by the latest photobiology research—will enable cultivators to achieve exceptional crop performance.”
The latest luminaires from Fluence include:
- SPYDR 2h: An extension of Fluence’s SPYDR series—featuring luminaires designed for single- or multitier growers who want to optimize grow space—the company’s high-output SPYDR 2h produces a photosynthetic photon flux of up to 2,080 μmol/s. Supported by results from Fluence’s multiyear global research studies observing cannabis growth under high light intensities, the SPYDR 2h is designed to maximize yields.
- SPYDR Fang: The SPYDR Fang is designed specifically for the retail buyer and built with Fluence’s trusted, research-backed and science-led engineering leveraged by commercial growers throughout the world.
- RAZR Enclosed: Following its debut in June 2021, the RAZR Modular System is now IP67 waterproof to withstand hyper-wet and humid environments within a vertical farm. The RAZR series is also now available with various spectral options, including broad-white as well as dual red and blue light. Fluence will showcase the system’s newest features through video at the company’s MJBizCon booth.
- RAPTR: Fluence’s latest top light solution serves as an advanced one-to-one high-pressure sodium replacement. The next-generation top light consumes 1,000 watts at a high output, plugging in seamlessly to a grower’s existing facility for streamlined retrofits.
“Fluence’s high-output SPYDR 2h will transform how cannabis cultivators approach each stage of plant production,” said Jordon Musser, chief product officer for Fluence. “We’ve seen incredible yield and quality metrics at high PPFDs and we’re excited to collaborate with our growers to incorporate high-intensity lighting and cultivation strategies into their operations.”
The company will also debut its innovative lighting controls, including:
- SHYFT: Available in North America, Fluence’s light scheduler, SHYFT, offers patented photoacclimation capability and daily photoperiod control for 0 to 10 V LED and dimmable fluorescent fixtures. At MJBizCon, visit the Fluence booth to see SHYFT control each of the company’s luminaires and witness its advanced lighting control capabilities.
- Wireless Flex Dimming: In addition to SHYFT, Fluence’s Wireless Flex Dimming solution leverages Bluetooth mesh technology to wirelessly control fixtures. With Wireless Flex Dimming’s plug-and-play design, growers gain increased flexibility over light levels with no wire installations or additional labor costs. Fluence team members will demo the product’s wireless capabilities from within the booth.
“MJBizCon is the world’s stage for unveiling leading cannabis innovations and we’re thrilled to debut multiple solutions that are advancing the global cannabis market forward,” said Lorrie Schultz, senior vice president of marketing for Fluence. “We’re eager to showcase our new products at MJBizCon and exemplify how Fluence is helping cannabis cultivators grow smarter.”
For more information on Fluence, its products and release dates for the company’s newest solutions, visit the team at MJBizCon from Oct. 20, 2021 to Oct. 22, 2021 at booth No. C3515 or explore Fluence’s website at www.fluence.science .
About Fluence by OSRAM
Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit https://fluence.science .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211019005390/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom